Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
69 results about "Regulatory peptide" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Compositions for mucosal and oral administration comprising HCG fragments
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.
Owner:BIOTEMPT
Bifidobacterium bifidum and application thereof
ActiveCN106834187AImprove toleranceIncrease the water content of fecesBacteriaDigestive systemSide effectFeces
The invention discloses bifidobacterium bifidum capable of remarkably relieving constipation and application thereof and belongs to the technical field of microorganisms. The bifidobacterium bifidum CGMCC NO.13632 can well tolerate simulative gastrointestinal fluid, can be well attached to colon cancer cells HT-29, and can remarkably increase the water content of excrement of constipation mice and shorten the first tarry stool time. On the aspect of increasing the small intestine driving rate, the bifidobacterium bifidum CGMCC NO.13632 is superior to cathartic phenolphthalein, a best effect is shown, secretion of gastrointestinal regulatory peptide relevant to constipation in serum is also adjusted while constipation pathological factors are remarkably improved, and the bifidobacterium bifidum does not have toxic and side effects of medicine for treating constipation, and is a first choice for preventing and treating constipation. The bifidobacterium bifidum CGMCC NO.13632 is used for preparing pharmaceutical compositions and fermented food for relieving constipation, and has very wide application prospects.
Owner:JIANGNAN UNIV
Gene regulatory peptides
InactiveUS20050214943A1Quick and easy approachThe process is simple and fastAntibacterial agentsAntipyreticSignalling moleculesExpression gene
The invention relates to the modulation of gene expression in a cell, also called gene control, in particular in relation to the treatment of a variety of diseases. The invention provides a method for modulating expression of a gene in a cell comprising providing the cell with a signaling molecule comprising a peptide or functional analogue thereof. Furthermore, the invention provides a method for identifying or obtaining a signaling molecule comprising a peptide or functional derivative or analogue thereof capable of modulating expression of a gene in a cell comprising providing the cell with a peptide or derivative or analogue thereof and determining the activity and / or nuclear translocation of a gene transcription factor.
Owner:BIOTEMPT
Treatment of iatrogenic disease
InactiveUS20080194489A1Maintain securityTetrapeptide ingredientsTripeptide ingredientsGeneMedical treatment
The invention relates to the field of human or veterinary medicine and to the treatment of subjects (be it man or animal) that suffer from iatrogenic disease, i.e., experience problems or complications resulting from a medical treatment. Provided is a method for modulating an iatrogenic event in a subject, the method comprising: providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, provided is the use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of an additional pro-inflammatory cytokine response occurring after an iatrogenic event in a subject.
Owner:BIOTEMPT
Treatment of multiple sclerosis (MS)
The invention relates to the treatment multiple sclerosis, and in particular to the treatment of the inflammatory injury seen in the progressive stages in the disease such as seen with the recurrent upsurges of acute disease, classically known as “relapses” or “exacerbations” or “relapsing / remitting” disease seen in multiple sclerosis. The invention provides a method for modulating a relapsing / remitting disease in a subject suffering therefrom involving providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides the use of an NF-κB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of relapsing / remitting disease as seen with multiple sclerosis.
Owner:BIOTEMPT
Treatment of type I diabetes
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.
Owner:BIOTEMPT
Compositions for mucosal and oral administration comprising hcg fragments
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.
Owner:BIOTEMPT
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
ActiveUS20050191296A1Facilitates the binding of a B7-2 ligandEliciting protective immunity against toxic shockCell receptors/surface-antigens/surface-determinantsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenBacterial exotoxin
Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28 / B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed. Also disclosed is the use of the CD28 molecule or any fragment thereof comprising the sAg binding site in a method of screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Bifidobacterium bifidum and its use
ActiveCN106834187BIncrease moisture contentImprove the first black stool timeBacteriaDigestive systemBiotechnologySide effect
Owner:JIANGNAN UNIV
Probiotic composition and preparation method and application thereof
ActiveCN113151056ASurprised by the technical effectRelieve constipation somatosensory effectBacteriaDigestive systemBiotechnologyProbiotic bacterium
The invention provides a probiotic composition and a preparation method and application thereof. The probiotic composition comprises raw materials of lactobacillus reuteri, lactobacillus acidophilus and bifidobacterium animalis, wherein the weight ratio of the lactobacillus reuteri to the lactobacillus acidophilus to the bifidobacterium animalis is (1.5-2.5):(0.5-1.5):(0.5-1.5). The colony forming units of the lactobacillus reuteri, the lactobacillus acidophilus or the bifidobacterium animalis in unit weight are the same. The lactobacillus reuteri is preserved in China Center for Type Culture Collection with the preservation number of 209138, and the lactobacillus acidophilus and / or the bifidobacterium animalis preserved in China General Microbiological Culture Collection Center with the preservation number of CGMCC 15210 are / is bifidobacterium animalis BB-115. The probiotic composition can relieve the symptom of slow transit constipation under the condition of low dosage, and can remarkably and effectively regulate gastrointestinal regulatory peptide indexes related to constipation, such as P substance (SP), gastrin (Gas) and vasoactive peptide (VIP).
Owner:SIRIO PHARMA CO LTD
Yao horsefly salivary gland immunoregulation peptide, gene and application thereof
ActiveCN101220091ASimple structureEasy to synthesizeImmunological disordersFermentationTyrosineAntibacterial activity
The invention relates to a salivary gland immunoregulation polypeptide of a dieu cleg and the related genes and the application, belonging to the biomedical field. The immunoregulation polypeptide is a linear polypeptide coded with the Chinese Tabanidae salivary gland immunoregulation polypeptide genes, the sequence of which is glycin- glycin- valine- serine- glycin- valine- serine- aspartic acid- phenylalanine- glutamate- praline- isoleucine- glutamate- valine- serine- glycin- glutamate- aspartic acid- tyrosine- aspartic acid- serine- aspartic acid- glutamate- alanine- aspartic acid- glutamate- aspartic acid- glycin- lysine- alanine. The immunoregulation polypeptide gene is composed of 362 Nucleotides, wherein, the coding mature code salivary gland immunoregulation polypeptide of the dieu cleg is the 115th to the 204th nucleotide. The dieu cleg salivary gland immunoregulation polypeptide is used for inhibiting a plurality of cytokines, which is characterized by simple structure, convenient artificial synthesis and strong antibacterial activity, etc.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Enzyme-labeled immunoassay kit and application of thereof to serum detection
InactiveCN103901192AWide range of substrate actionImprove heat resistanceChemiluminescene/bioluminescencePeptide preparation methodsPotentiatorRegulatory peptide
The invention discloses an enzyme-labeled immunoassay kit which comprises an antibody pre-coating reaction plate, an enzyme-labeled antibody and luminous substrate liquid, wherein the enzyme-labeled antibody takes SBP (soybean protease) as marker enzyme; the luminous substrate liquid comprises H2O2, luminol and an enhancer; the enhancer consists of MORPH (4-marlene pyridine) and SPTZ (3-(10'-phenothiazinyl) propyl-1-sulfonate). According to the enzyme-labeled immunoassay kit, the SBP is introduced to serve as the marker enzyme; on one hand, the thermal stability of the enzyme is higher than that of HRP (hypothalamic regulatory peptide), and the enzyme has the advantages of wide substrate working range, high heat resistance, high acid-alkaline stability, wide pH application range and the like; on the other hand, when the enhancers MORPH and SPTZ are used for enhancing chemical illumination, a chemical luminous signal is enhanced by nearly 100 times, and the detection sensitivity is greatly improved.
Owner:靖江市人民医院 +1
Peptide complexes containing phospholipase d
The present invention provides peptide complexes comprising phospholipase D and one or morephospholipase D-interacting peptides. The peptide complexes are useful in screening assays foridentifying compounds effective in modulating the peptide complexes and in treating and / or preventing diseases associated with phospholipase D and it's interacting partners. In addition, methods for screening modulators of the peptide complexes or interacting members thereof are provided.
Owner:POSTECH ACAD IND FOUND
Photoregulated peptide, and method for regulation of peptide-protein complex formation using the photoregulated peptide
InactiveUS20090042235A1Peptide/protein ingredientsMicrobiological testing/measurementEpitopeADAMTS Proteins
The present invention provides a method of photoregulating the formation of a peptide-protein complex by using a novel peptide in which a structural change for recognizing a protein is photoregulated, in the formation of a complex between a peptide capable of recognizing a protein and a protein of interest. A peptide having an intramolecular cross-linkage via a photocleavable cross-linking group, and method for producing the same. Further, a peptide which has an intramolecular cross-linkage via a photocleavable cross-linking group and forms a cyclic structure together with the cross-linking group, containing a peptide having an epitope corresponding to a functional protein or a ligand at a part which forms the cyclic structure, and method for producing the same. A reaction regulation method comprising the steps of: irradiating a peptide which comprises a peptide having the above epitope, with light to cause cleavage of the photocleavable cross-linking group, whereby dissociating the cyclic structure; and initiating a reaction between the peptide in which the cyclic structure has dissociated and the functional protein or the ligand to form a complex.
Owner:SHIMADZU CORP
3D Printing and Drug Delivery
InactiveUS20190321291A1High stiffnessLow viscosityInfusion syringesAerosol deliverySupporting cellDrug delivery
A 3D structure of a hydrogel for supporting cell growth or for use in sustained drug delivery is formed using peptides and / or peptide derivatives that self-assemble via cross-linking into a stiff gel. The hydrogel structure is formed using a method based on 3D printing. A hydrogel precursor is extruded under conditions to generate a hydrogel, by extruding a solution of the peptides into a solution containing cations, whereby the cations enable cross-linking of pi-stacked peptides, or by co-extruding it with the cations, the peptides and cations being mixed only at the point of co-extrusion. The stiffness of the hydrogel can be tuned by adjusting the combination of peptides, either by the selection of peptides or combinations thereof, or the proportions of the combinations, and / or by adjusting the proportion of cations present.
Owner:BIOGELX
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between CD28 and the superantigen and uses thereof
ActiveUS8535672B2Facilitates the binding of a B7-2 ligandEliciting protective immunity against toxic shockCell receptors/surface-antigens/surface-determinantsImmunoglobulins against cell receptors/antigens/surface-determinantsAntigenDimer
Disclosed are methods and compositions for the inhibition of modulation of T cell costimulatory pathway by a pathogenic agent, particularly, the inhibition of activation of a T cell costimulatory pathway, preferably, the CD28 / B7 pathway, by a pyrogenic exotoxin. The method of the invention is based on the inhibition of the direct interaction of a superantigen with a specific site within the dimer interface of a CD28 family member, using immunomodulatory peptides. Further disclosed are specific antagonist immunomodulatory peptides comprising an amino acid sequence derived from a dimer interface of a T cell co-stimulatory pathway member, or peptides which comprise an amino acid sequence which specifically binds to an amino acid sequence within the dimer interface of a T cell co-stimulatory pathway member. Compositions comprising said peptides and methods for the treatment of immune-related disorders are also disclosed.Also disclosed is the use of the CD28 molecule or any fragment thereof comprising the sAg binding site in a method of screening for a test substance which specifically binds to the CD28 molecule and is capable of antagonizing pyrogenic exotoxin-mediated activation of Th1 lymphocytes.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
R. grahami rnmunoregulating polypeptide, gene and variant and its application in medicine production
InactiveCN101037473AEasy to synthesizeSimple structurePeptidesCyclic peptide ingredientsImmunomodulationsIsoelectric point
The invention relates to an Odorrana grahami immunomodulation peptide, gene and variant and the application in the pharmacy belonging to the biomedicine field. The Odorrana grahami immunomodulation peptide is a circular peptide with a molecular weight of 1791.12 D and a isoelectric point of 9.84. The whole sequence of the Odorrana grahami immunomodulation peptide is Thr Ser Arg Cys Tyr Ile Gly Tyr Arg Arg Lys Val Val Cys Ser (TSRCYIGYRRKVVCS), wherein the fourth cysteine and 14th cysteine form intramolecular disulfide bond. The code gene is composed of 307 nucleotides, wherein the code mature parts are from 141th to 186th nucleotide. The produced variant is produced by substituting the fourth amino acid in the original sequence of the Odorrana grahami immunomodulation peptide. The artificial synthetic Odorrana grahami immunomodulation peptide and variant thereof has a strong immunomodulation activity and tumor resistance activity and can be used for immunomodulation, tumor treatment and chemotherapeutics. The invention has the advantages such as simple sequence and convenient synthesis.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Acetylcholinesterase-derived peptides and uses thereof
The invention relates to a cell growth and / or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. The invention also relates to pharmaceutical compositions comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and / or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradiation conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals. Further, the invention relates to antibodies against the peptides, inter alia for diagnostic use, for example, the diagnosis of stress-induced male infertility. The invention also relates to in vitro and in vivo methods for screening of drugs that affect the central nervous system, and are potential modulators of interactions between the “readthrough” form of acetylcholinesterase, AChE-R, the intracellular receptor RACK1 and the kinase PKC.
Owner:SOREQ HERMONA +4
Solid-phase competition ELISA reagent kit of antibody for O-typed foot and mouth disease virus based on specific monoclonal antibody
InactiveCN106405092ASolve inter-type crossoverFix stability issuesBiological material analysisImmunoglobulins against virusesElisa methodGuinea pig
The invention discloses a solid-phase competition ELISA reagent kit of an antibody for an O-typed foot and mouth disease virus based on a specific monoclonal antibody, which comprises an O-typed foot and mouth disease specific monoclonal antibody marked by HRP (hypothalamic regulatory peptides). The reagent kit of the invention can be used for monitoring a level of the antibody for the O-typed foot and mouth disease virus. By replacing a rabbit antibody, guinea pig antiserum and guinea pig enzyme mark antibody in existing ELISA, the invention simplifies the steps of the ELISA method, improves stability, and greatly shorten detection time from 24 h to 1.5 h or less, thereby breaking through reaction processes for a primary antibody and a second antibody required by original ELISA.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Prokineticin 2 as biomarker for psoriasis and its use
ActiveCN106324259AConvenient treatmentPeptide/protein ingredientsDisease diagnosisWound healingMedicine
The invention relates to an endogenous regulatory peptide prokineticin 2 (PK2) as a biomarker for psoriasis and its use, and belongs to the field of medical molecular biology. The inventor found that PK2 has a new biological function that promotes wound healing and psoriasis by detecting the expression of PK2 in the blood and skin of psoriasis as a biomarker for detecting the occurrence or development of psoriasis. The invention also relates to the use of PK2 in the treatment or detection of psoriasis and its use in wound healing. The invention has found that PK2 has the function of promoting the occurrence of psoriasis and can detect the occurrence or development of psoriasis by detecting the expression of PK2 in skin and blood of psoriasis. PK2 can be used as the specificity biomarker of the occurrence or development of psoriasis; PK2 as a target has a very good effect on the treatment of psoriasis, and the treatment of psoriasis provides a new target. In addition, the invention also relates to the activity of PK2 to promote wound healing and to provide a new drug template for wound healing.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof
ActiveUS20140011731A1Facilitates the binding of a B7-2 ligandEliciting protective immunity against toxic shockCell receptors/surface-antigens/surface-determinantsPeptide/protein ingredientsDimerAntigen
Owner:YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD
Peptide regulators of mitochondrial fusion and methods of use
ActiveUS10578610B2Easy to transportIncrease mitochondrial aspect ratioPolypeptide with localisation/targeting motifCompound screeningDiseaseMFN2
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +1
Immunoregulation peptide, and preparation method and application thereof
InactiveCN104530212AStimulates the proliferation of T lymphocytesLow immunityMilk preparationPeptide/protein ingredientsImmunomodulatory peptideMedicine
The invention belongs to the fields of medicine and bioengineering, and discloses an immunoregulation peptide, and a preparation method and application thereof. The amino acid sequence of the immunoregulation is disclosed as SEQ ID NO:1. The immunoregulation peptide has high T lymphopoiesis promoting function, and can be used for preparing T lymphopoiesis promoting drugs.
Owner:NANJING MATERNITY & CHILD HEALTH CARE HOSPITAL
ELISA (Enzyme-linked Immunosorbent Assay) kit for detecting methotrexate and application thereof
InactiveCN107219357ASmall standard deviationChromatography mass spectrometry is easyMaterial analysisSerum igeElisa kit
The invention provides an ELISA (Enzyme-linked Immunosorbent Assay) kit for detecting methotrexate and application thereof. The kit is prepared from the following reagents: a methotrexate coated 96-pore microporous plate, a methotrexate monoclonal antibody, an antibody diluting solution, an HRP (Hypothalamic Regulatory Peptide)-labeled goat anti-mouse secondary antibody, a methotrexate standard product, a washing liquid concentrated solution, a sample diluting solution, a TMB (Tetramethylbenzidine) color-developing solution and a stopping solution. The stable, rapid and simple methotrexate detection kit is obtained through improving the combination of all reagents and improvement on parameters of the reagents; when the ELISA kit is applied, the standard deviation value of the kit is relatively small. The ELISA kit can be used for detecting the plasma drug concentration of patients who utilize the methotrexate with a large dosage and detecting the plasma drug concentration of patients who utilize the methotrexate with a small dosage.
Owner:THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Prodomain modulators of ADAM 10
The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.
Owner:BIOZYME +1
Methods of Treating or Preventing Tissue Damage Caused by Increased Blood Flow
InactiveUS20090169538A1Avoid tissue damageNervous disorderPeptide/protein ingredientsBinding peptideActinin binding
A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta 4 (TB4), an isoform of TB4, an N-terminal fragment of TB4, a C-terminal fragment of TB4, TB4 sulfoxide, an LKKTET [SEQ ID NO: 1] peptide, an LKKTNT [SEQ ID NO: 2] peptide, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a conservative variant thereof having tissue damage-reducing activity. The composition is administered to the tissue before, during and / or after affecting the increase in blood flow.
Owner:REGENERX BIOPHARMACEUTICALS INC
Application of regulatory peptide and mansonone E in preparation of improved medicament for treating leukemia and application of regulatory peptide and mansonone E
ActiveCN109865125ASmall doseLittle side effectsPeptide/protein ingredientsInorganic active ingredientsUse medicationSide effect
The invention relates to a regulatory peptide and mansonone E in preparation of an improved medicament for treating leukemia and application of the regulatory peptide and the mansonone E. Through model screening, the regulatory peptide capable of promoting the activity of the mansonone E is obtained, the regulatory peptide and the mansonone E are combined to prepare the medicament for treating leukemia. The medicament has the advantages of being small in dosage, moderate in cost, convenient to take, small in side effect and the like.
Owner:THE PEOPLES HOSPITAL SHAANXI PROV
Acetylcholinesterase-derived peptides and uses thereof
The invention relates to a cell growth and / or differentiation regulatory peptide comprising a sequence of about 9 to about 150 amino acids derived from acetylcholinesterase amino acid sequence, preferably from the C-terminal region of acetylcholinesterase. The invention also relates to pharmaceutical compositions comprising the peptides, particularly for use in promoting survival of stem cells, promoting differentiation of stem cells, promoting growth of stem cells and / or promoting the growth-enhancing effect of a growth factor on stem cells, alone, or in combination with other growth factors. Of particular interest is the use of the peptides in the treatment of thrombocytopenia, post-irradiation conditions, post-chemotherapy conditions, or conditions following massive blood loss and promotion of neural progenitors in use for cell therapies aimed at restoring neural functions in diseased individuals. Further, the invention relates to antibodies against the peptides, inter alia for diagnostic use, for example, the diagnosis of stress-induced male infertility. The invention also relates to in vitro and in vivo methods for screening of drugs that affect the central nervous system, and are potential modulators of interactions between the “readthrough” form of acteylcholinesterase, AChE-R, the intracellular receptor RACK1 and the kinase PKC.
Owner:YISSUM RES DEV CO OF THE HEBREWUNIVERSITY OF JERUSALEM LTD
Composition for removing tumor immunosuppression and application thereof
ActiveCN110732021ALifting of immunosuppressionDisinhibitionPeptide/protein ingredientsGenetically modified cellsReceptorCD80
The invention discloses a composition for removing tumor immunosuppression and application thereof. The composition provided by the invention comprises following (a) to (e) components or coded nucleicacid thereof: (a) IL-15, a mutant thereof or functional fragments thereof; (b) an IL-15 receptor alpha, a mutant thereof or functional fragments thereof; (c) IL-12, a mutant thereof or functional fragments thereof; (d) TGF-beta regulatory peptide, a mutant thereof or functional fragments thereof; and (e) PD1-CD80 fusion protein, a mutant thereof or functional fragments thereof. According to the composition provided by the invention, the immune response of T lymphocytes can be improved synergistically.
Owner:BEIJING TRICISIONBIO THERAPEUTICS INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com